絞り込み

16424

広告

こんぴら歌舞伎へ 八代目中村芝翫さんが意気込み (NHK)

香川県琴平町にある国内最古の芝居小屋で毎年春に行われる「四国こんぴら歌舞伎大芝居」の製作発表の会見が24日、東京で開かれ、襲名披露の公演となる八代目中村芝翫さん...

  1. ~日本とベトナム 再生医療技術協力が拡大...
  2. 「火山は日本にとって恵みだ」。 知の巨人...
  3. 乾癬治療、新しい飲み薬が四半世紀ぶり登場...
  4. 太地町イルカ追い込みで姉妹都市 (デイリ...

ニュース一覧

SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier.

著者 Kawano M , Matsui M , Handa H
Expert Rev Vaccines.2013 Feb ; 12(2):199-210.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Department of Immunology, Faculty of Medicine, Saitama Medical University, Moroyama-cho, Iruma-gun, Saitama 350-0495, Japan.

スターを付ける スターを付ける     (480view , 0users)

Full Text Sources

The authors have purified a major capsid protein, VP1 of Simian virus 40 (SV40), using recombinant baculovirus and have established the method of in vitro reassembly of SV40 virus-like particles (SV40-VLPs) from VP1-pentamers. In this reassembly, SV40-VLPs can encapsulate approximately 5 kb exogenous DNA shielded by histone or foreign proteins fused to minor capsid proteins VP2/3 and effectively deliver them into mammalian cells. Insertion of a particular foreign peptide into the surface loops of VP1 provides SV40-VLPs with the ability of cell targeting. Furthermore, SV40-VLPs appear to stimulate innate immunity as a natural adjuvant. Given these characteristics, SV40-VLPs may be a promising vaccine carrier to deliver heterologous antigens for the induction of cytotoxic T lymphocytes without artificial adjuvants. In this review, the authors describe how SV40-VLPs have been developed and engineered, and discuss their potential benefits and challenges as a cytotoxic T lymphocyte-based vaccine platform.
PMID: 23414410 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード